MedTrace Logo

A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)

NCT03669393 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-09-02

No results posted yet for this study

Summary

This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in reducing central subfield thickness (CST) and improving best-corrected visual acuity (BCVA) in subjects with macular telangiectasia Type 1 (MacTel 1).

Conditions

  • Retinal Telangiectasis
  • Idiopathic Juxtafoveal Retinal Telangiectasia

Interventions

DRUG

THR-317 8mg

3 intravitreal injections of THR-317 8mg, approximately 1 month apart

Sponsors & Collaborators

  • ThromboGenics

    lead INDUSTRY

Principal Investigators

  • Clinical Department · Oxurion NV.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-18
Primary Completion
2019-11-22
Completion
2019-11-22

Countries

  • France
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03669393 on ClinicalTrials.gov